Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase Ila Multiple Basket Study (vol 36, pg 536, 2018)

被引：0
|
作者：
Burris, Howard A.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.18.02263
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：360 / 360
页数：1
相关论文
共 50 条
  • [1] Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
    Hainsworth, John D.
    Meric-Bernstam, Funda
    Swanton, Charles
    Hurwitz, Herbert
    Spigel, David R.
    Sweeney, Christopher
    Burris, Howard
    Bose, Ron
    Yoo, Bongin
    Stein, Alisha
    Beattie, Mary
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06) : 536 - +
  • [2] Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study.
    Hainsworth, John D.
    Meric-Bernstam, Funda
    Swanton, Charles
    Hurwitz, Herbert
    Spigel, David R.
    Sweeney, Christopher
    Burris, Howard A.
    Bose, Ron
    Guo, Shuangli
    Bernaards, Coen
    Beattie, Mary Stanley
    Stein, Alisha
    Brammer, Melissa
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
  • [3] Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study.
    Hainsworth, John D.
    Meric-Bernstam, Funda
    Swanton, Charles
    Hurwitz, Herbert
    Spigel, David R.
    Sweeney, Christopher
    Burris, Howard A.
    Bose, Ron
    Guo, Shuangli
    Bernaards, Coen
    Beattie, Mary Stanley
    Stein, Alisha
    Brammer, Melissa
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors.
    Hurwitz, Herbert
    Hainsworth, John D.
    Swanton, Charles
    Perez, Edith A.
    Sweeney, Christopher
    Burris, Howard A.
    Spigel, David
    Meric-Bernstam, Funda
    Strickland, Donald K.
    Leon, Larry
    Brammer, Melissa
    Beattie, Mary Stanley
    Bose, Ron
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [5] Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study
    Kurzrock, R.
    Bowles, D. W.
    Kang, H.
    Meric-Bernstam, F.
    Hainsworth, J.
    Spigel, D. R.
    Bose, R.
    Burris, H.
    Sweeney, C. J.
    Beattie, M. S.
    Blotner, S.
    Schulze, K.
    Cuchelkar, V
    Swanton, C.
    ANNALS OF ONCOLOGY, 2020, 31 (03) : 412 - 421
  • [6] Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
    Friedman, Claire F.
    Hainsworth, John D.
    Kurzrock, Razelle
    Spigel, David R.
    Burris, Howard A., III
    Sweeney, Christopher J.
    Meric-Bernstam, Funda
    Wang, Yong
    Levy, Jonathan
    Grindheim, Jessica
    Shames, David S.
    Schulze, Katja
    Patel, Arisha
    Swanton, Charles
    CANCER DISCOVERY, 2022, 12 (03) : 654 - 669
  • [7] Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)
    Jiao, Xiao-Dong
    Qin, Bao-Dong
    Wang, Zhan
    Liu, Ke
    Wu, Ying
    Ling, Yan
    Qin, Wen-Xing
    Wang, Miao-Miao
    Yuan, Ling-Yan
    Barreto, Savio George
    Kim, Anthony W.
    Mak, Kimberley
    Li, Hao
    Xu, Yuan-Yuan
    Qiu, Xiao-Ming
    Wu, Min
    Jin, Min
    Xu, Li-Chao
    Zhong, Yi
    Yang, Hui
    Chen, Xue-Qin
    Zeng, Yu
    Shi, Jun
    Zhu, Wen-Yu
    Ding, Qing-Qing
    Jia, Wei
    Liu, Su-Fen
    Zhou, Jun-Jing
    Shen, Hong
    Yao, Shi-Hua
    Guo, Zhao-Ji
    Li, Ting
    Zhou, Pei-Juan
    Dong, Xue-Wei
    Lu, Wen-Feng
    Coleman, Robert L.
    Akce, Mehmet
    Akladios, Cherif
    Puccetti, Francesco
    Zang, Yuan-Sheng
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [8] Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
    Simonelli, M.
    Garralda, E.
    Eskens, F.
    Gil-Martin, M.
    Yen, C-J
    Obermannova, R.
    Chao, Y.
    Lonardi, S.
    Melichar, B.
    Moreno, V
    Yu, M-L
    Bongiovanni, A.
    Calvo, E.
    Rottey, S.
    Machiels, J-P
    Gonzalez-Martin, A.
    Paz-Ares, L.
    Chang, C-L
    Mason, W.
    Lin, C-C
    Reardon, D. A.
    Vieito, M.
    Santoro, A.
    Meng, R.
    Abbadessa, G.
    Menas, F.
    Lee, H.
    Liu, Q.
    Combeau, C.
    Ternes, N.
    Ziti-Ljajic, S.
    Massard, C.
    ESMO OPEN, 2022, 7 (05)
  • [9] MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents.
    Burris, Howard A.
    Hurwitz, Herbert
    Perez, Edith A.
    Spigel, David
    Swanton, Charles
    Hainsworth, John D.
    Leon, Larry
    Beattie, Mary
    Brammer, Melissa
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.
    Cousin, Sophie
    Blay, Jean-Yves
    Garcia, Irene Brana
    De Bono, Johann S.
    Le Tourneau, Christophe
    Moreno, Victor
    Trigo, Jose Manuel
    Hann, Christine L.
    Azad, Arun
    Im, Seock-Ah
    Ferron-Brady, Geraldine
    Datta, Antara
    Wu, Yuehui
    Horner, Thierry
    Kremer, Brandon Edward
    Dhar, Arindam
    O'Dwyer, Peter J.
    Shapiro, Geoffrey
    Piha-Paul, Sarina Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345